Printer Friendly

CURATEK ANNOUNCES SALE OF METROGEL TO PURSUE NEW PRODUCT OPPORTUNITIES

 ELK GROVE VILLAGE, Ill., June 30 /PRNewswire/ -- Curatek Pharmaceuticals Limited Partnership announced today that it has sold MetroGel (0.75 percent metronidazole topical gel), a prescription drug therapy for rosacea, to Galderma Laboratories, Inc. in order to pursue additional new product opportunities.
 "While MetroGel has been highly successful, proceeds from the sale will enable Curatek to expand its licensing and acquisition activities for potential new products," said Dr. Robert Borgman, president of Curatek. He noted that the company plans to place special emphasis on acquiring late-stage product development programs and currently marketed pharmaceuticals in the initial stages of their life cycles.
 "We are especially interested in products with a specialist orientation and whose market potential is below the threshold for large pharmaceutical companies," said John Presutti, Curatek vice president.
 Curatek developed and submitted the New Drug Application (NDA) for MetroGel, and received marketing approval from the Food and Drug Administration (FDA) in late 1988. Since its introduction by Curatek, MetroGel has become the most widely prescribed therapy in the United States for rosacea, an acne-like disease that commonly first apepars after age 30. Physicians and consumer education programs have significantly increased the number of patients now diagnosed and treated for this condition.
 The sale of MetroGel will not affect employment at Curatek, which will continue to market MetroGel-Vaginal (metronidazole vaginal gel, 0.75 percent) for bacterial vaginosis and pursue ongoing new product development programs. MetroGel-Vaginal was introduced in the U.S. in the fall of 1992 and is now the leading intravaginal therapy for bacterial vaginosis, believed to be the most common form of vaginal infection.
 Galderma Laboratories, Inc. is headquartered in Fort Worth, Texas.
 Curatek is a privately held, research-based company engaged in developing and marketing specialized pharmaceutical products.
 -0- 6/30/93
 /CONTACT: John Presutti, 708-806-7680, or Sam Huff, 708-382-7404, of Curatek/


CO: Curatek Pharmaceuticals Limited Partnership; Galderma Laboratories,
 Inc. ST: Illinois, Texas IN: MTC SU:


LG -- NY039 -- 7139 06/30/93 11:57 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1993
Words:327
Previous Article:R.R. DONNELLEY TO INCREASE VIRGINIA BOOK PLANT'S CAPACITY BY 50 PERCENT TO MEET TRADE, COLLEGE DEMAND
Next Article:KAISER ALUMINUM COMPLETES SALE OF NEW EQUITY


Related Articles
CURATEK ANNOUNCES FDA APPROVAL OF NEW THERAPY FOR BACTERIAL VAGINOSIS
3M to Acquire Leading Gynecological Product
Galderma USA Announces New Product for the Topical Treatment of Rosacea.
Fougera Receives First Tentative Generic Approval for MetroGel(R).
New MetroGel formulation offers advantages in rosacea.
GTCR Announces Graceway Pharmaceuticals' Completed Acquisition of 3M's Pharmaceutical Business in North and Latin America.
Galderma USA Introduces New Kit For Rosacea Treatment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters